Boston Scientific (BSX)

Business Overview

Boston Scientific is where growth bought through acquisitions is easiest to see among the cardiovascular device makers. FY2025 net sales were $20,074M. Reported growth was +19.9% and organic growth 15.8%, a 4.1-point gap: 3.4 points from acquisitions and 0.7 from currency.

The segments show the effect more sharply than the group. Urology grew +23.1% reported but +4.7% organic; the reconciliation table in the FY2025 earnings release puts 17.9 of the 18.4 points down to acquisitions. Cardiovascular grew +23.2% reported and +20.8% organic, a 2.4-point gap. The organic growth guide builds its screening method around the Urology split.

GAAP gross margin was 69.0% (70.6% adjusted). GAAP operating margin was 18.0% and adjusted 28.0%. R&D was $2,052M, 10.2% of sales on GAAP (9.5% adjusted).

How the Numbers Read

Organic definition. Boston Scientific's organic growth excludes foreign exchange and acquisitions or divestitures owned for less than one full comparable period. Medtronic (4.9% organic, year to 25 April 2025) also strips deals, on its own definition, but Boston Scientific's pace of deals makes the gap visible at group and segment level.

Free cash flow ($3.7B non-GAAP, 80% conversion). Company-defined non-GAAP free cash flow was $3.659B, an 80% conversion rate, inside the company's 70-80% long-range target. Cash conversion held up in a year when reported growth overstated underlying growth.

WATCHMAN (more than 600,000 cumulative patients treated). WATCHMAN is an implant that closes off a pouch in the heart's left atrium, cutting stroke risk for patients with an irregular heartbeat. The patient count is a treatment milestone. Boston Scientific files no group installed-base figure. The installed-base guide separates milestones like this from placed-system counts such as Intuitive's 11,106 da Vinci systems.

Recurring mix, not filed. No consolidated recurring or consumable share is filed, and Cardiovascular and Urology revenue both blend capital and consumables. Only Intuitive Surgical files a group recurring share (84%); for Boston Scientific the recurring economics have to be inferred from segment mix.

Valuation Framework

Any growth-adjusted P/E for Boston Scientific should divide by 15.8% organic growth, not 19.9% reported. Dividing by the reported rate lowers the ratio and credits the business with growth it bought. Bain links roughly 2 turns of forward EV multiple to each 100 bps of revenue growth for medtech above $3B revenue (valuations as of 14 January 2024), which is why the growth input matters so much. The growth-adjusted P/E guide works the method on a fictional example.

What to Watch in the Financials

The gap between reported and organic (4.1 points for the group). A quarter where reported growth speeds up while organic stalls is acquisitions at work. Urology (+23.1% reported, +4.7% organic) is the template.

Cardiovascular organic growth (+20.8%). The segment driving the group rate. Its gap to reported (+23.2%) is small; watch whether it widens as deals continue.

FCF conversion (80%). At the top of the 70-80% target, so there is little room above it.

Adjusted operating margin (28.0%). Management's benchmark is the non-GAAP margin. GAAP at 18.0% is the one that compares across peers, so track both.

Key Risks

Integration and organic fade. Acquisitions that lift reported growth can hide a slow underlying franchise, as Urology's +4.7% organic shows. Missed synergy targets show up in the organic lines before the reported ones.

Cardiovascular competition. Medtronic, Abbott and Johnson & Johnson compete in electrophysiology (treating heart-rhythm disorders), and Abbott competes with WATCHMAN. Boston Scientific stopped selling its ACURATE TAVR valves in 2025. Whether +20.8% organic growth in Cardiovascular lasts is the open question.

Reliance on non-GAAP. The FCF and margin figures management leads with are adjusted. On GAAP, operating margin is 18.0%, and a reader has to judge which adjustments recur and which are deal-related.

What the Screening Shows

Against the Medtech Sector Primer screens:

• Organic growth: 15.8% organic against 19.9% reported (4.1-point gap: acquisitions 3.4, currency 0.7). Use organic in any growth-adjusted screen.
• Urology: +4.7% organic / +23.1% reported, the widest gap in the filed segments.
• Gross margin: 69.0% GAAP / 70.6% adjusted.
• FCF: $3.7B non-GAAP; 80% conversion (70-80% target).
• WATCHMAN: more than 600,000 cumulative patients treated (a treatment milestone).
• Recurring mix: not filed at group level.

When the group headline looks strong, Urology at +4.7% organic is the segment check. Cardiovascular, at +20.8% organic and two-thirds of sales, is the line that drives the group rate.